CCEL — what changed in the latest 10-Q
A section-by-section comparison of CCEL's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-07-15 vs the prior 10-Q · 2026-04-14
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +25 | −15 | ~12 | 75 |
| Controls & procedures | Text added/removed | 0 | −1 | ~2 | 3 |
| Legal proceedings | Text added/removed | 0 | 0 | ~1 | 1 |
| Risk factors | Some risk factors updated | +1 | −1 | ~3 | 4 |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3)
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-07-15
Processing and Storage Fees. For six months ended May 31, 2026 and May 31, 2025 processing and storage fees were $15,358,559 and $15,737,607, respectively. The decrease in processing and storage fee revenue is attributable to a 3% increase in recurring annual storage fee revenue offset by a 14% decr…
Product Revenue. For the six months ended May 31, 2026, revenue from the product sales was $52,776 compared to $35,349 for the six months ended May 31, 2025.
Public Cord Blood Banking Revenue. For the six months ended May 31, 2026, revenue from the public cord blood banking sales was $47,895 compared to $124,767 for the six months ended May 31, 2025. The change in revenue is due to the volatility of customer demand.
Cost of Sales. Cost of sales for the six months ended May 31, 2026 was $3,333,151 as compared to $3,841,127 for the same period in 2025, representing a 13% decrease. Cost of sales includes wages and supplies associated with process enhancements to the existing production procedures and quality syste…
Selling, General and Administrative Expenses. Selling, general and administrative expenses for the six months ended May 31, 2026 were $9,629,846 as compared to $8,896,142 for the 2025 period representing a 8% increase. These expenses are primarily comprised of selling and marketing expenses, salarie…
Text removed vs the prior filing · source: 10-Q · 2026-04-14
Revenue. Revenue for the three months ended February 28, 2026 was $7,683,117 as compared to $7,968,880 for the same period in 2025 a decrease of 4% as a result of the reasons discussed below.
Processing and Storage Fees. For the three months ended February 28, 2026, processing and storage fees were $7,643,113 compared to $7,865,888 for the three months ended February 28, 2025. Processing and storage fee revenue is attributable to a 3% decrease in recurring annual storage fee revenue offs…
Product Revenue. For the three months ended February 28, 2026, revenue from the product sales was $38,594 compared to $20,913 for the three months ended February 28, 2025.
Public Cord Blood Banking Revenue. For the three months ended February 28, 2026, revenue from the public cord blood banking sales was $1,410 compared to $82,079 for the three months ended February 28, 2025.
Cost of Sales. Cost of sales for the three months ended February 28, 2026 was $1,656,488 as compared to $1,984,588 for the same period in 2025, representing a 17% decrease. Cost of sales includes wages and supplies associated with process enhancements to the existing production procedures and qualit…
Controls & procedures
Text removed vs the prior filing · source: 10-Q · 2026-04-14
deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-07-15
The Company may not regain compliance with the continued listing requirements.
Text removed vs the prior filing · source: 10-Q · 2026-04-14
NYSE American may not accept the Company’s Plan of Compliance
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice